Inovio Pharmaceuticals, Inc. (NYSEMKT:INO)’s Influenza DNA Vaccine shows positive results

866

Dallas, Texas 07/17/2013 (Financialstrend) – Inovio Pharmaceuticals, Inc. (NYSEMKT: INO) has been successful in developing a vaccine which protects the animals from sickness & death, the first vaccine of its type in the universe of pharmaceutical developments. The recent preclinical study which was conducted by INO for Influenza DNA Vaccine to save animals from getting infected with the newly emerging H7N9 Flu virus presented 100% successful results.

It was observed that all the animals used for this purpose of the study were successfully secluded against the infection from the virus and thus protected against the related sickness & death, when they were subject to a dosage of the medicine, in concert with a lethal dosage of H7N9 virus The firm has generated income of $-20.30 million in last 12 months and sales of $3.90 million. Analytic Ratios – Price to sales ratio of INO in past 12 months was calculated as 49.25 and price to cash as 6.84. The company return on equity ratio is recorded as -57.60% and its return on assets is -41.30%. INO has announced the peer-reviewed journal of outcome of its PENNVAX-B precautionary HIV DNA vaccine undergoing phase I clinical trials that is HVTN 070 and HVTN 080 which are delivered with a DNA adjuvant and with or without Inovio’s proprietary CELLECTRA Electroporation delivery device.

Shares of Inovio Pharmaceuticals, Inc. opened at $1.30 per share on Tuesday and thereafter decreased by 3.88% to close at $1.24 for the day. There had been intraday price movements in the stock within the range of $1.21 as low price to $1.34 as high price. Inovio Pharmaceuticals has 52 week low at $0.44 and 52 week high at $1.57 per share. The company has 179.92 million shares outstanding in the market which gives it a market cap of $223.10 million and there is institutional ownership in the capital at 12% of the stock. Inovio Pharmaceuticals witnessed the trade of 4.77 million shares on Tuesday, while the average level is at 4.77 million shares per day.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.